|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland.
|
31606444 |
2020 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
To report 10-year, real-world experiences with intravitreal therapy (IVT) using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration (nAMD).
|
31282617 |
2020 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD).
|
30986442 |
2020 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes.
|
31589766 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
|
30529685 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD).
|
31055948 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3-year visual acuity (VA) outcomes.
|
30149035 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration.
|
31367847 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using this model, we investigated the retinal responses to VEGF-Trap (Aflibercept), an anti-angiogenic agent recognizing ligands of VEGF receptors 1 and 2 that possesses regulatory approval for the treatment of neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion and diabetic macular edema.
|
31550048 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
|
29324593 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
|
30901385 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
|
31088111 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated the characteristic changes in optical coherence tomography (OCT) biomarkers in neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor drugs and their relationship with visual outcomes at 1-year follow-up in a real-world setting.
|
30679743 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the synergistic benefits and cost savings from the use of optical coherence tomography (OCT) and vascular endothelial growth factor (VEGF) inhibitors, particularly intravitreal bevacizumab, in the treatment of exudative age-related macular degeneration (AMD).
|
30851267 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the prevalence and characteristics associated with macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with vascular endothelial growth factor (VEGF) inhibitors.
|
31843790 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema.
|
31792234 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor A (VEGFA) is involved in the pathogenesis of vasoproliferative retinal diseases, such as exudative age-related macular degeneration (AMD).
|
30825671 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication.
|
30030393 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
|
30844038 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist.
|
30788433 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
|
30999772 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
|
31613840 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
|
30834517 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of treatment assignment (intravitreal aflibercept vs ranibizumab) and baseline characteristics with fellow eye conversion to nAMD in the VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies.
|
31294771 |
2019 |
|
Exudative age-related macular degeneration
|
0.100 |
Biomarker
|
disease |
BEFREE |
Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.
|
30077616 |
2019 |